ZVSA
What one share of Zyversa Therapeutics holds
Pharmaceutical Preparations
Zyversa Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-03-31; the balance sheet is as of 2026-03-31.
| Profit | −$3.40 |
|---|---|
| Cash and investments | $0.04 |
| Book value | −$1.74 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2023 | — | −$1,090 | — | −$89.44 | — | — |
| 2024 | — | −$8.48 | — | −$6.77 | — | — |
| 2025 | — | −$4.18 | — | −$0.86 | — | −$1.53 |